Goldman Sachs’s Evogene EVGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-2,911
| Closed | -$48K | – | 6650 |
|
|
2021
Q4 | $48K | Buy |
2,911
+402
| +16% | +$9.12K | ﹤0.01% | 6273 |
|
|
2021
Q3 | $66K | Sell |
2,509
-1,178
| -32% | -$34.4K | ﹤0.01% | 5992 |
|
|
2021
Q2 | $126K | Sell |
3,687
-978
| -21% | -$38.3K | ﹤0.01% | 5891 |
|
|
2021
Q1 | $235K | Buy |
+4,665
| New | +$289K | ﹤0.01% | 5571 |
|
|
2020
Q3 | – | Sell |
-76,718
| Closed | -$767K | – | 5372 |
|
|
2020
Q2 | $767K | Hold |
76,718
| – | – | ﹤0.01% | 4133 |
|
|
2020
Q1 | $905K | Buy |
76,718
+2,700
| +4% | +$37.2K | ﹤0.01% | 3827 |
|
|
2019
Q4 | $1.13M | Sell |
74,018
-2,700
| -4% | -$40.3K | ﹤0.01% | 4048 |
|
|
2019
Q3 | $1.21M | Hold |
76,718
| – | – | ﹤0.01% | 3903 |
|
|
2019
Q2 | $1.24M | Hold |
76,718
| – | – | ﹤0.01% | 3858 |
|
|
2019
Q1 | $1.4M | Buy |
76,718
+40,000
| +109% | +$846K | ﹤0.01% | 3866 |
|
|
2018
Q4 | $727K | Sell |
36,718
-3
| -0% | -$76 | ﹤0.01% | 4158 |
|
|
2018
Q3 | $1.14M | Buy |
36,721
+24,987
| +213% | +$722K | ﹤0.01% | 3965 |
|
|
2018
Q2 | $336K | Buy |
11,734
+10,005
| +579% | +$305K | ﹤0.01% | 4718 |
|
|
2018
Q1 | $55K | Sell |
1,729
-13
| -0.7% | -$484 | ﹤0.01% | 5451 |
|
|
2017
Q4 | $53K | Buy |
+1,742
| New | +$68.4K | ﹤0.01% | 5924 |
|
|
2017
Q3 | – | Sell |
-28,918
| Closed | -$1.46M | – | 6704 |
|
|
2017
Q2 | $1.46M | Sell |
28,918
-31,778
| -52% | -$1.64M | ﹤0.01% | 4109 |
|
|
2017
Q1 | $3.25M | Buy |
60,696
+22,678
| +60% | +$1.18M | ﹤0.01% | 3312 |
|
|
2016
Q4 | $1.94M | Sell |
38,018
-10,086
| -21% | -$577K | ﹤0.01% | 3883 |
|
|
2016
Q3 | $3.07M | Hold |
48,104
| – | – | ﹤0.01% | 3457 |
|
|
2016
Q2 | $3M | Sell |
48,104
-83
| -0.2% | -$5.78K | ﹤0.01% | 3267 |
|
|
2016
Q1 | $3.14M | Buy |
48,187
+169
| +0.4% | +$11.6K | ﹤0.01% | 3098 |
|
|
2015
Q4 | $3.87M | Buy |
48,018
+9,000
| +23% | +$669K | ﹤0.01% | 3076 |
|
|
2015
Q3 | $3.22M | Buy |
39,018
+6,809
| +21% | +$593K | ﹤0.01% | 3309 |
|
|
2015
Q2 | $2.85M | Hold |
32,209
| – | – | ﹤0.01% | 3490 |
|
|
2015
Q1 | $2.84M | Hold |
32,209
| – | – | ﹤0.01% | 3448 |
|
|
2014
Q4 | $2.97M | Buy |
32,209
+26,500
| +464% | +$2.81M | ﹤0.01% | 3462 |
|
|
2014
Q3 | $751K | Sell |
5,709
-17,925
| -76% | -$2.47M | ﹤0.01% | 4907 |
|
|
2014
Q2 | $3.87M | Sell |
23,634
-2,772
| -10% | -$477K | ﹤0.01% | 3315 |
|
|
2014
Q1 | $5.03M | Sell |
26,406
-77,500
| -75% | -$14.7M | ﹤0.01% | 3017 |
|
|
2013
Q4 | $20.4M | Buy |
+103,906
| New | +$19.2M | 0.01% | 1730 |
|
Other funds holding EVGN
SM
EVC
VIA
Goldman Sachs's EVGN Position: Q1 2022 in Review
Goldman Sachs sold out of Evogene (EVGN) in Q1 2022, closing a stake of 2,911 shares — an estimated $48K sold.
Goldman Sachs first reported a position in EVGN in Q4 2013 and held it in 30 quarters. The position peaked at $20.4M in Q4 2013. 38 funds tracked by Wall St. Rank hold EVGN as of Q1 2022.
- Goldman Sachs reported no remaining Evogene position as of Q1 2022 after selling out during the quarter.
- Goldman Sachs sold 2,911 Evogene shares in Q1 2022, an estimated $48K.
- Goldman Sachs first reported a position in Evogene in Q4 2013 and held it in 30 quarters.
- Goldman Sachs's Evogene position peaked at $20.4M in Q4 2013.
- 38 funds tracked by Wall St. Rank held Evogene as of Q1 2022.
Based on Goldman Sachs's 13F filing for Q1 2022, filed 16 May 2022.